Company / Accounts Receivable
United Therapeutics Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$350.2M
FY2025
5-year range
$198.7M / $350.2M
FY2021-FY2025
Trend
+25.4%
vs FY2024
Sector context
#27 of 113
Health Care
What the data says
United Therapeutics's accounts receivable of $350M is higher than 76% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 6 consecutive years, from $151M in FY2019 to $350M in FY2025.
Based on SEC 10-K filings.
$350M in FY2025 with a 5-year CAGR of +17.3%. Top quartile in the Health Care sector.
Improved from $279M to $350M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- +17.3%
- 10-Year CAGR
- -
Sector benchmark
-69.2% below sector average
Key checks
Key Insights
- United Therapeutics's accounts receivable has grown for 6 consecutive years.
- 5-year CAGR of +17.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 25.4% year-over-year.
- Ranks #27 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $350.2M | +25.4% |
| FY2024 | $279.3M | +0.1% |
| FY2023 | $278.9M | +26.5% |
| FY2022 | $220.4M | +10.9% |
| FY2021 | $198.7M | +26.2% |
| FY2020 | $157.4M | +4.0% |
| FY2019 | $151.4M | -13.8% |
| FY2018 | $175.7M | -40.9% |
| FY2017 | $297.1M | +38.5% |
| FY2016 | $214.5M | +11.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026